FMC - Elk Grove Dialysis Ctr in Elk Grove Village, Illinois - Dialysis Center

FMC - Elk Grove Dialysis Ctr is a medicare approved dialysis facility center in Elk Grove Village, Illinois and it has 28 dialysis stations. It is located in Cook county at 901 Biesterfield Road Ste 400, Elk Grove Village, IL, 60007. You can reach out to the office of FMC - Elk Grove Dialysis Ctr at (847) 437-0824. This dialysis clinic is managed and/or owned by Fresenius Medical Care. FMC - Elk Grove Dialysis Ctr has the following ownership type - Profit. It was first certified by medicare in September, 1977. The medicare id for this facility is 142507 and it accepts patients under medicare ESRD program.

Dialysis Center Profile

NameFMC - Elk Grove Dialysis Ctr
Location901 Biesterfield Road Ste 400, Elk Grove Village, Illinois
No. of Dialysis Stations 28
Medicare ID142507
Managed ByFresenius Medical Care
Ownership TypeProfit
Late Shifts No

Contact Information


901 Biesterfield Road Ste 400, Elk Grove Village, Illinois, 60007
(847) 437-0824

News Archive

Genzyme announces publication of phase 2 clinical trial results of eliglustat tartrate for Gaucher disease

Genzyme Corporation announced today that the two-year follow-up results from the phase 2 clinical trial of its investigational therapy known as eliglustat tartrate have been accepted for publication in the journal Blood. The results have been pre-published on the journal's website and are available to subscribers.

Back App: A training apparatus for Sitting Disease

Scientific research is increasingly showing strong links between spending too much time sitting and the development of severe long and short term health problems.

HM Hospitales expects to treat first patients with Elekta's Versa HD system in 2015

HM Hospitales, a private hospital group in Spain, anticipates treating its first patients with Elekta's Versa HD™ system in 2015. Versa HD, to be sited in the group's sixth hospital, is an advanced radiation treatment system designed to enhance the management of cancer care and treat a broad spectrum of tumors throughout the body.

BRI receives JDRF grant to explore why people with type 1 diabetes continue to produce insulin

Scientists at Benaroya Research Institute at Virginia Mason are studying a critical question in type 1 diabetes: Why do some people who get type 1 diabetes continue to produce small amounts of insulin over time while others stop? Researchers have found at the time of diagnosis with type 1 diabetes that many people continue to produce small amounts of insulin.

New tool refines heart risk prediction

For about 10 years, the Framingham risk score has been used to estimate a person's chances of having a heart attack based on just six bits of information - age, sex, total cholesterol, HDL cholesterol, smoking status, and systolic blood pressure.

Read more Medical News

› Verified 5 days ago


Map and Direction



NPI Associated with this Dialysis Facility:

Dialysis Facilities may have multiple NPI numbers. We have found possible NPI number/s associated with FMC - Elk Grove Dialysis Ctr from NPPES records by matching pattern on the basis of name, address, phone number etc. Please use this information accordingly.

NPI Number1023123866
Organization NameElk Grove Dialysis Center
Doing Business AsWskc Dialysis Services, Inc.
Address901 Biesterfield Rd Elk Grove Village, Illinois, 60007
Phone Number(847) 437-0824

News Archive

Genzyme announces publication of phase 2 clinical trial results of eliglustat tartrate for Gaucher disease

Genzyme Corporation announced today that the two-year follow-up results from the phase 2 clinical trial of its investigational therapy known as eliglustat tartrate have been accepted for publication in the journal Blood. The results have been pre-published on the journal's website and are available to subscribers.

Back App: A training apparatus for Sitting Disease

Scientific research is increasingly showing strong links between spending too much time sitting and the development of severe long and short term health problems.

HM Hospitales expects to treat first patients with Elekta's Versa HD system in 2015

HM Hospitales, a private hospital group in Spain, anticipates treating its first patients with Elekta's Versa HD™ system in 2015. Versa HD, to be sited in the group's sixth hospital, is an advanced radiation treatment system designed to enhance the management of cancer care and treat a broad spectrum of tumors throughout the body.

BRI receives JDRF grant to explore why people with type 1 diabetes continue to produce insulin

Scientists at Benaroya Research Institute at Virginia Mason are studying a critical question in type 1 diabetes: Why do some people who get type 1 diabetes continue to produce small amounts of insulin over time while others stop? Researchers have found at the time of diagnosis with type 1 diabetes that many people continue to produce small amounts of insulin.

New tool refines heart risk prediction

For about 10 years, the Framingham risk score has been used to estimate a person's chances of having a heart attack based on just six bits of information - age, sex, total cholesterol, HDL cholesterol, smoking status, and systolic blood pressure.

Read more Medical News

› Verified 5 days ago


Survey of Patient's Experiences

Nephrologists Performance Ratings

Experience MeasureProviderNational Avg.
Patients who reported that nephrologists always communicated and cared for them.61%67%
Patients who reported that nephrologists usually communicated and cared for them.19%15%
Patients who reported that nephrologists sometimes or never communicated and cared for them.20%18%
Patients who gave their nephrologists a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible).53%60%
Patients who gave their nephrologists a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible).30%26%
Patients who gave their nephrologists a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible).17%14%

News Archive

Genzyme announces publication of phase 2 clinical trial results of eliglustat tartrate for Gaucher disease

Genzyme Corporation announced today that the two-year follow-up results from the phase 2 clinical trial of its investigational therapy known as eliglustat tartrate have been accepted for publication in the journal Blood. The results have been pre-published on the journal's website and are available to subscribers.

Back App: A training apparatus for Sitting Disease

Scientific research is increasingly showing strong links between spending too much time sitting and the development of severe long and short term health problems.

HM Hospitales expects to treat first patients with Elekta's Versa HD system in 2015

HM Hospitales, a private hospital group in Spain, anticipates treating its first patients with Elekta's Versa HD™ system in 2015. Versa HD, to be sited in the group's sixth hospital, is an advanced radiation treatment system designed to enhance the management of cancer care and treat a broad spectrum of tumors throughout the body.

BRI receives JDRF grant to explore why people with type 1 diabetes continue to produce insulin

Scientists at Benaroya Research Institute at Virginia Mason are studying a critical question in type 1 diabetes: Why do some people who get type 1 diabetes continue to produce small amounts of insulin over time while others stop? Researchers have found at the time of diagnosis with type 1 diabetes that many people continue to produce small amounts of insulin.

New tool refines heart risk prediction

For about 10 years, the Framingham risk score has been used to estimate a person's chances of having a heart attack based on just six bits of information - age, sex, total cholesterol, HDL cholesterol, smoking status, and systolic blood pressure.

Read more Medical News

› Verified 5 days ago

Dialysis Center Staff Performance Ratings

Experience MeasureProviderNational Avg.
Patients who reported that dialysis center staff always communicated well, kept patients comfortable and pain-free as possible.62%62%
Patients who reported that dialysis center staff usually communicated, kept patients comfortable and pain-free as possible.19%20%
Patients who reported that dialysis center staff sometimes or never communicated, kept patients comfortable and pain-free.19%18%
Patients who gave their dialysis facility staff a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible).63%62%
Patients who gave their dialysis facility staff a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible).27%26%
Patients who gave their dialysis facility staff a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible).10%12%

News Archive

Genzyme announces publication of phase 2 clinical trial results of eliglustat tartrate for Gaucher disease

Genzyme Corporation announced today that the two-year follow-up results from the phase 2 clinical trial of its investigational therapy known as eliglustat tartrate have been accepted for publication in the journal Blood. The results have been pre-published on the journal's website and are available to subscribers.

Back App: A training apparatus for Sitting Disease

Scientific research is increasingly showing strong links between spending too much time sitting and the development of severe long and short term health problems.

HM Hospitales expects to treat first patients with Elekta's Versa HD system in 2015

HM Hospitales, a private hospital group in Spain, anticipates treating its first patients with Elekta's Versa HD™ system in 2015. Versa HD, to be sited in the group's sixth hospital, is an advanced radiation treatment system designed to enhance the management of cancer care and treat a broad spectrum of tumors throughout the body.

BRI receives JDRF grant to explore why people with type 1 diabetes continue to produce insulin

Scientists at Benaroya Research Institute at Virginia Mason are studying a critical question in type 1 diabetes: Why do some people who get type 1 diabetes continue to produce small amounts of insulin over time while others stop? Researchers have found at the time of diagnosis with type 1 diabetes that many people continue to produce small amounts of insulin.

New tool refines heart risk prediction

For about 10 years, the Framingham risk score has been used to estimate a person's chances of having a heart attack based on just six bits of information - age, sex, total cholesterol, HDL cholesterol, smoking status, and systolic blood pressure.

Read more Medical News

› Verified 5 days ago

Overall Dialysis Center Performance Ratings

Experience MeasureProviderNational Avg.
Patients who reported that 'YES', their nephrologists and dialysis center staff provided them the information they needed to take care of them. 76%80%
Patients who reported that 'NO', their nephrologists and dialysis center staff does not provided them the information they needed to take care of them.24%20%
Patients who gave their dialysis center a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible).64%68%
Patients who gave their dialysis center a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible).29%20%
Patients who gave their dialysis center a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible).7%12%

News Archive

Genzyme announces publication of phase 2 clinical trial results of eliglustat tartrate for Gaucher disease

Genzyme Corporation announced today that the two-year follow-up results from the phase 2 clinical trial of its investigational therapy known as eliglustat tartrate have been accepted for publication in the journal Blood. The results have been pre-published on the journal's website and are available to subscribers.

Back App: A training apparatus for Sitting Disease

Scientific research is increasingly showing strong links between spending too much time sitting and the development of severe long and short term health problems.

HM Hospitales expects to treat first patients with Elekta's Versa HD system in 2015

HM Hospitales, a private hospital group in Spain, anticipates treating its first patients with Elekta's Versa HD™ system in 2015. Versa HD, to be sited in the group's sixth hospital, is an advanced radiation treatment system designed to enhance the management of cancer care and treat a broad spectrum of tumors throughout the body.

BRI receives JDRF grant to explore why people with type 1 diabetes continue to produce insulin

Scientists at Benaroya Research Institute at Virginia Mason are studying a critical question in type 1 diabetes: Why do some people who get type 1 diabetes continue to produce small amounts of insulin over time while others stop? Researchers have found at the time of diagnosis with type 1 diabetes that many people continue to produce small amounts of insulin.

New tool refines heart risk prediction

For about 10 years, the Framingham risk score has been used to estimate a person's chances of having a heart attack based on just six bits of information - age, sex, total cholesterol, HDL cholesterol, smoking status, and systolic blood pressure.

Read more Medical News

› Verified 5 days ago

Patient Distribution

Anemia Management

Dialysis patients with Hemoglobin data84
Medicare patients who had average hemoglobin (hgb) less than 10 g/dL15

News Archive

Genzyme announces publication of phase 2 clinical trial results of eliglustat tartrate for Gaucher disease

Genzyme Corporation announced today that the two-year follow-up results from the phase 2 clinical trial of its investigational therapy known as eliglustat tartrate have been accepted for publication in the journal Blood. The results have been pre-published on the journal's website and are available to subscribers.

Back App: A training apparatus for Sitting Disease

Scientific research is increasingly showing strong links between spending too much time sitting and the development of severe long and short term health problems.

HM Hospitales expects to treat first patients with Elekta's Versa HD system in 2015

HM Hospitales, a private hospital group in Spain, anticipates treating its first patients with Elekta's Versa HD™ system in 2015. Versa HD, to be sited in the group's sixth hospital, is an advanced radiation treatment system designed to enhance the management of cancer care and treat a broad spectrum of tumors throughout the body.

BRI receives JDRF grant to explore why people with type 1 diabetes continue to produce insulin

Scientists at Benaroya Research Institute at Virginia Mason are studying a critical question in type 1 diabetes: Why do some people who get type 1 diabetes continue to produce small amounts of insulin over time while others stop? Researchers have found at the time of diagnosis with type 1 diabetes that many people continue to produce small amounts of insulin.

New tool refines heart risk prediction

For about 10 years, the Framingham risk score has been used to estimate a person's chances of having a heart attack based on just six bits of information - age, sex, total cholesterol, HDL cholesterol, smoking status, and systolic blood pressure.

Read more Medical News

› Verified 5 days ago

Dialysis Adequacy

Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.

  • Hemodialysis
    Adult patients getting regular hemodialysis at the center161
    Adult patient months included in Kt/V greater than or equal to 1.21463
    Percentage of adult patients getting regular hemodialysis at the center99
    Percentage of pediatric patients getting regular hemodialysis at the center

    News Archive

    Genzyme announces publication of phase 2 clinical trial results of eliglustat tartrate for Gaucher disease

    Genzyme Corporation announced today that the two-year follow-up results from the phase 2 clinical trial of its investigational therapy known as eliglustat tartrate have been accepted for publication in the journal Blood. The results have been pre-published on the journal's website and are available to subscribers.

    Back App: A training apparatus for Sitting Disease

    Scientific research is increasingly showing strong links between spending too much time sitting and the development of severe long and short term health problems.

    HM Hospitales expects to treat first patients with Elekta's Versa HD system in 2015

    HM Hospitales, a private hospital group in Spain, anticipates treating its first patients with Elekta's Versa HD™ system in 2015. Versa HD, to be sited in the group's sixth hospital, is an advanced radiation treatment system designed to enhance the management of cancer care and treat a broad spectrum of tumors throughout the body.

    BRI receives JDRF grant to explore why people with type 1 diabetes continue to produce insulin

    Scientists at Benaroya Research Institute at Virginia Mason are studying a critical question in type 1 diabetes: Why do some people who get type 1 diabetes continue to produce small amounts of insulin over time while others stop? Researchers have found at the time of diagnosis with type 1 diabetes that many people continue to produce small amounts of insulin.

    New tool refines heart risk prediction

    For about 10 years, the Framingham risk score has been used to estimate a person's chances of having a heart attack based on just six bits of information - age, sex, total cholesterol, HDL cholesterol, smoking status, and systolic blood pressure.

    Read more Medical News

    › Verified 5 days ago

Mineral and Bone Disorder

An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at FMC - Elk Grove Dialysis Ctr with elevated calcium levels.

Patients with hypercalcemia169
Hypercalcemia patient months1535
Patients with Serumphosphor177
Patients with Serumphosphor less than 3.5 mg/dL6
Patients with Serumphosphor from 3.5 to 4.5 mg/dL28
Patients with Serumphosphor from 4.6 to 5.5 mg/dL32
Patients with Serumphosphor from 5.6 to 7 mg/dL22
Patients with Serumphosphor greater than 7 mg/dL11

News Archive

Genzyme announces publication of phase 2 clinical trial results of eliglustat tartrate for Gaucher disease

Genzyme Corporation announced today that the two-year follow-up results from the phase 2 clinical trial of its investigational therapy known as eliglustat tartrate have been accepted for publication in the journal Blood. The results have been pre-published on the journal's website and are available to subscribers.

Back App: A training apparatus for Sitting Disease

Scientific research is increasingly showing strong links between spending too much time sitting and the development of severe long and short term health problems.

HM Hospitales expects to treat first patients with Elekta's Versa HD system in 2015

HM Hospitales, a private hospital group in Spain, anticipates treating its first patients with Elekta's Versa HD™ system in 2015. Versa HD, to be sited in the group's sixth hospital, is an advanced radiation treatment system designed to enhance the management of cancer care and treat a broad spectrum of tumors throughout the body.

BRI receives JDRF grant to explore why people with type 1 diabetes continue to produce insulin

Scientists at Benaroya Research Institute at Virginia Mason are studying a critical question in type 1 diabetes: Why do some people who get type 1 diabetes continue to produce small amounts of insulin over time while others stop? Researchers have found at the time of diagnosis with type 1 diabetes that many people continue to produce small amounts of insulin.

New tool refines heart risk prediction

For about 10 years, the Framingham risk score has been used to estimate a person's chances of having a heart attack based on just six bits of information - age, sex, total cholesterol, HDL cholesterol, smoking status, and systolic blood pressure.

Read more Medical News

› Verified 5 days ago

Vascular Access

The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.

Patients included in arterial venous fistula and catheter summaries 132
Patient months included in arterial venous fistula and catheter summaries 1120
Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment62
Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer14

News Archive

Genzyme announces publication of phase 2 clinical trial results of eliglustat tartrate for Gaucher disease

Genzyme Corporation announced today that the two-year follow-up results from the phase 2 clinical trial of its investigational therapy known as eliglustat tartrate have been accepted for publication in the journal Blood. The results have been pre-published on the journal's website and are available to subscribers.

Back App: A training apparatus for Sitting Disease

Scientific research is increasingly showing strong links between spending too much time sitting and the development of severe long and short term health problems.

HM Hospitales expects to treat first patients with Elekta's Versa HD system in 2015

HM Hospitales, a private hospital group in Spain, anticipates treating its first patients with Elekta's Versa HD™ system in 2015. Versa HD, to be sited in the group's sixth hospital, is an advanced radiation treatment system designed to enhance the management of cancer care and treat a broad spectrum of tumors throughout the body.

BRI receives JDRF grant to explore why people with type 1 diabetes continue to produce insulin

Scientists at Benaroya Research Institute at Virginia Mason are studying a critical question in type 1 diabetes: Why do some people who get type 1 diabetes continue to produce small amounts of insulin over time while others stop? Researchers have found at the time of diagnosis with type 1 diabetes that many people continue to produce small amounts of insulin.

New tool refines heart risk prediction

For about 10 years, the Framingham risk score has been used to estimate a person's chances of having a heart attack based on just six bits of information - age, sex, total cholesterol, HDL cholesterol, smoking status, and systolic blood pressure.

Read more Medical News

› Verified 5 days ago

Hospitalization Rate

The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.

Standard Hospitalization Summary Ratio(SHR) YearJanuary, 2016 - December, 2016
Patients in facility's Hospitalization Summary151
Hospitalization Rate in facility164.8 (As Expected)
Hospitalization Rate: Upper Confidence Limit260.4
Hospitalization Rate: Lower Confidence Limit111.8

News Archive

Genzyme announces publication of phase 2 clinical trial results of eliglustat tartrate for Gaucher disease

Genzyme Corporation announced today that the two-year follow-up results from the phase 2 clinical trial of its investigational therapy known as eliglustat tartrate have been accepted for publication in the journal Blood. The results have been pre-published on the journal's website and are available to subscribers.

Back App: A training apparatus for Sitting Disease

Scientific research is increasingly showing strong links between spending too much time sitting and the development of severe long and short term health problems.

HM Hospitales expects to treat first patients with Elekta's Versa HD system in 2015

HM Hospitales, a private hospital group in Spain, anticipates treating its first patients with Elekta's Versa HD™ system in 2015. Versa HD, to be sited in the group's sixth hospital, is an advanced radiation treatment system designed to enhance the management of cancer care and treat a broad spectrum of tumors throughout the body.

BRI receives JDRF grant to explore why people with type 1 diabetes continue to produce insulin

Scientists at Benaroya Research Institute at Virginia Mason are studying a critical question in type 1 diabetes: Why do some people who get type 1 diabetes continue to produce small amounts of insulin over time while others stop? Researchers have found at the time of diagnosis with type 1 diabetes that many people continue to produce small amounts of insulin.

New tool refines heart risk prediction

For about 10 years, the Framingham risk score has been used to estimate a person's chances of having a heart attack based on just six bits of information - age, sex, total cholesterol, HDL cholesterol, smoking status, and systolic blood pressure.

Read more Medical News

› Verified 5 days ago

Readmission Rate

The rate of readmission show you whether patients who were being treated regularly at FMC - Elk Grove Dialysis Ctr were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.

Standard Readmission Summary Ratio(SRR) YearJanuary, 2016 - December, 2016
Readmission Rate in facility18 (As Expected)
Readmission Rate: Upper Confidence Limit25.1
Readmission Rate: Lower Confidence Limit12.2

News Archive

Genzyme announces publication of phase 2 clinical trial results of eliglustat tartrate for Gaucher disease

Genzyme Corporation announced today that the two-year follow-up results from the phase 2 clinical trial of its investigational therapy known as eliglustat tartrate have been accepted for publication in the journal Blood. The results have been pre-published on the journal's website and are available to subscribers.

Back App: A training apparatus for Sitting Disease

Scientific research is increasingly showing strong links between spending too much time sitting and the development of severe long and short term health problems.

HM Hospitales expects to treat first patients with Elekta's Versa HD system in 2015

HM Hospitales, a private hospital group in Spain, anticipates treating its first patients with Elekta's Versa HD™ system in 2015. Versa HD, to be sited in the group's sixth hospital, is an advanced radiation treatment system designed to enhance the management of cancer care and treat a broad spectrum of tumors throughout the body.

BRI receives JDRF grant to explore why people with type 1 diabetes continue to produce insulin

Scientists at Benaroya Research Institute at Virginia Mason are studying a critical question in type 1 diabetes: Why do some people who get type 1 diabetes continue to produce small amounts of insulin over time while others stop? Researchers have found at the time of diagnosis with type 1 diabetes that many people continue to produce small amounts of insulin.

New tool refines heart risk prediction

For about 10 years, the Framingham risk score has been used to estimate a person's chances of having a heart attack based on just six bits of information - age, sex, total cholesterol, HDL cholesterol, smoking status, and systolic blood pressure.

Read more Medical News

› Verified 5 days ago

Infection Rate

Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at FMC - Elk Grove Dialysis Ctr get infections in their blood each year compared to the number of infections expected for the center based on the national average.

Standard Infection Summary Ratio(SIR) YearJanuary, 2016 - December, 2016
Infection Rate in facility.67 (As Expected)
SIR: Upper Confidence Limit1.32
SIR: Lower Confidence Limit.29

News Archive

Genzyme announces publication of phase 2 clinical trial results of eliglustat tartrate for Gaucher disease

Genzyme Corporation announced today that the two-year follow-up results from the phase 2 clinical trial of its investigational therapy known as eliglustat tartrate have been accepted for publication in the journal Blood. The results have been pre-published on the journal's website and are available to subscribers.

Back App: A training apparatus for Sitting Disease

Scientific research is increasingly showing strong links between spending too much time sitting and the development of severe long and short term health problems.

HM Hospitales expects to treat first patients with Elekta's Versa HD system in 2015

HM Hospitales, a private hospital group in Spain, anticipates treating its first patients with Elekta's Versa HD™ system in 2015. Versa HD, to be sited in the group's sixth hospital, is an advanced radiation treatment system designed to enhance the management of cancer care and treat a broad spectrum of tumors throughout the body.

BRI receives JDRF grant to explore why people with type 1 diabetes continue to produce insulin

Scientists at Benaroya Research Institute at Virginia Mason are studying a critical question in type 1 diabetes: Why do some people who get type 1 diabetes continue to produce small amounts of insulin over time while others stop? Researchers have found at the time of diagnosis with type 1 diabetes that many people continue to produce small amounts of insulin.

New tool refines heart risk prediction

For about 10 years, the Framingham risk score has been used to estimate a person's chances of having a heart attack based on just six bits of information - age, sex, total cholesterol, HDL cholesterol, smoking status, and systolic blood pressure.

Read more Medical News

› Verified 5 days ago

Transfusion Summary

Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether FMC - Elk Grove Dialysis Ctr's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.

Standard Transfusion Summary Ratio (STrR) Year January, 2016 - December, 2016
Patients in facility's Transfusion Summary 126
Transfusion Rate in facility19.5 (As Expected)
Transfusion Rate: Upper Confidence Limit48.5
Transfusion Rate: Lower Confidence Limit8.8

News Archive

Genzyme announces publication of phase 2 clinical trial results of eliglustat tartrate for Gaucher disease

Genzyme Corporation announced today that the two-year follow-up results from the phase 2 clinical trial of its investigational therapy known as eliglustat tartrate have been accepted for publication in the journal Blood. The results have been pre-published on the journal's website and are available to subscribers.

Back App: A training apparatus for Sitting Disease

Scientific research is increasingly showing strong links between spending too much time sitting and the development of severe long and short term health problems.

HM Hospitales expects to treat first patients with Elekta's Versa HD system in 2015

HM Hospitales, a private hospital group in Spain, anticipates treating its first patients with Elekta's Versa HD™ system in 2015. Versa HD, to be sited in the group's sixth hospital, is an advanced radiation treatment system designed to enhance the management of cancer care and treat a broad spectrum of tumors throughout the body.

BRI receives JDRF grant to explore why people with type 1 diabetes continue to produce insulin

Scientists at Benaroya Research Institute at Virginia Mason are studying a critical question in type 1 diabetes: Why do some people who get type 1 diabetes continue to produce small amounts of insulin over time while others stop? Researchers have found at the time of diagnosis with type 1 diabetes that many people continue to produce small amounts of insulin.

New tool refines heart risk prediction

For about 10 years, the Framingham risk score has been used to estimate a person's chances of having a heart attack based on just six bits of information - age, sex, total cholesterol, HDL cholesterol, smoking status, and systolic blood pressure.

Read more Medical News

› Verified 5 days ago

Survival Summary

The rate of mortality show you whether patients who were being treated regularly at FMC - Elk Grove Dialysis Ctr lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.

Standard Survival Summary Ratio(SIR) YearJanuary, 2013 - December, 2016
Patients in facility's Survival Summary722
Mortality Rate in facility15.3 (As Expected)
Mortality Rate: Upper Confidence Limit18.8
Mortality Rate: Lower Confidence Limit12.4

News Archive

Genzyme announces publication of phase 2 clinical trial results of eliglustat tartrate for Gaucher disease

Genzyme Corporation announced today that the two-year follow-up results from the phase 2 clinical trial of its investigational therapy known as eliglustat tartrate have been accepted for publication in the journal Blood. The results have been pre-published on the journal's website and are available to subscribers.

Back App: A training apparatus for Sitting Disease

Scientific research is increasingly showing strong links between spending too much time sitting and the development of severe long and short term health problems.

HM Hospitales expects to treat first patients with Elekta's Versa HD system in 2015

HM Hospitales, a private hospital group in Spain, anticipates treating its first patients with Elekta's Versa HD™ system in 2015. Versa HD, to be sited in the group's sixth hospital, is an advanced radiation treatment system designed to enhance the management of cancer care and treat a broad spectrum of tumors throughout the body.

BRI receives JDRF grant to explore why people with type 1 diabetes continue to produce insulin

Scientists at Benaroya Research Institute at Virginia Mason are studying a critical question in type 1 diabetes: Why do some people who get type 1 diabetes continue to produce small amounts of insulin over time while others stop? Researchers have found at the time of diagnosis with type 1 diabetes that many people continue to produce small amounts of insulin.

New tool refines heart risk prediction

For about 10 years, the Framingham risk score has been used to estimate a person's chances of having a heart attack based on just six bits of information - age, sex, total cholesterol, HDL cholesterol, smoking status, and systolic blood pressure.

Read more Medical News

› Verified 5 days ago


Dialysis Facility in Elk Grove Village, IL

FMC - Elk Grove Dialysis Ctr
Location: 901 Biesterfield Road Ste 400, Elk Grove Village, Illinois, 60007
Phone: (847) 437-0824
FMC - Elk Grove Home Dialysis Center
Location: 901 Biesterfield Road Suite 401, Elk Grove Village, Illinois, 60007
Phone: (847) 952-9866
Affiliated Home Dialysis Of Elk Grove
Location: 1014 Bonaventure Drive, Elk Grove Village, Illinois, 60007
Phone: (847) 352-4711

News Archive

Genzyme announces publication of phase 2 clinical trial results of eliglustat tartrate for Gaucher disease

Genzyme Corporation announced today that the two-year follow-up results from the phase 2 clinical trial of its investigational therapy known as eliglustat tartrate have been accepted for publication in the journal Blood. The results have been pre-published on the journal's website and are available to subscribers.

Back App: A training apparatus for Sitting Disease

Scientific research is increasingly showing strong links between spending too much time sitting and the development of severe long and short term health problems.

HM Hospitales expects to treat first patients with Elekta's Versa HD system in 2015

HM Hospitales, a private hospital group in Spain, anticipates treating its first patients with Elekta's Versa HD™ system in 2015. Versa HD, to be sited in the group's sixth hospital, is an advanced radiation treatment system designed to enhance the management of cancer care and treat a broad spectrum of tumors throughout the body.

BRI receives JDRF grant to explore why people with type 1 diabetes continue to produce insulin

Scientists at Benaroya Research Institute at Virginia Mason are studying a critical question in type 1 diabetes: Why do some people who get type 1 diabetes continue to produce small amounts of insulin over time while others stop? Researchers have found at the time of diagnosis with type 1 diabetes that many people continue to produce small amounts of insulin.

New tool refines heart risk prediction

For about 10 years, the Framingham risk score has been used to estimate a person's chances of having a heart attack based on just six bits of information - age, sex, total cholesterol, HDL cholesterol, smoking status, and systolic blood pressure.

Read more Medical News

› Verified 5 days ago


Find & Compare Providers Near You: Find and compare doctors, nursing homes, hospitals, and other health care providers in your area that accept Medicare. Get information like: Find a doctor or clinician that accepts Medicare near you.

Doctors and clinicians: Doctors and clinicians include doctors, clinicians and groups who are qualified to practice in many specialties. Each specialty focuses on certain parts of the body, periods of life, conditions, or primary care. The doctors, clinicians, and groups listed here typically work in an office or clinic setting. Also those who currently accept Medicare are included.

Hospitals: Find information about Medicare-certified hospitals and long-term care hospitals in your area, including Veterans Administration medical centers and military hospitals, across the country. Long-term care hospitals serve critically ill and medically complex patients who require extended hospital care.

Data provided: Information on www.medicareusa.org is built using open data sources published by Centers for Medicare & Medicaid Services (CMS) under Freedom of Information Act (FOIA).

© 2024 MedicareUsa. All rights reserved. Maintained by the Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services.